CLASS ACTION UPDATE for WBK, BDX and INO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / March 17, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

WBK Shareholders Click Here: https://www.zlk.com/pslra-1/westpac-banking-corporation-loss-form?prid=5714&wire=1
BDX Shareholders Click Here: https://www.zlk.com/pslra-1/becton-dickinson-company-loss-form?prid=5714&wire=1
INO Shareholders Click Here: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=5714&wire=1

* ADDITIONAL INFORMATION BELOW *

Westpac Banking Corporation (NYSE:WBK)

WBK Lawsuit on behalf of: investors who purchased November 11, 2015 - November 19, 2019
Lead Plaintiff Deadline : March 30, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/westpac-banking-corporation-loss-form?prid=5714&wire=1

According to the filed complaint, during the class period, Westpac Banking Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) contrary to Australian law, the Company failed to report over 19.5 million international funds transfer instructions to the Australian Transaction Reports and Analysis Centre ("AUSTRAC"); (2) the Company did not appropriately monitor and assess the ongoing money laundering and terrorism financing risks associated with movement of money into and out of Australia; (3) the Westpac did not pass on requisite information about the source of funds to other banks in the transfer chain; (4) despite being aware of the heightened risks, the Company did not carry out appropriate due diligence on transactions in South East Asia and the Philippines that had known financial indicators relating to child exploitation risks; (5) the Company's Anti-Money Laundering and Counter-Terrorism Financing Policy Program was inadequate to identify, mitigate and manage money laundering and terrorism financing risks; and (6) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Becton Dickinson & Company (NYSE:BDX)

BDX Lawsuit on behalf of: investors who purchased November 5, 2019 - February 5, 2020
Lead Plaintiff Deadline : April 27, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/becton-dickinson-company-loss-form?prid=5714&wire=1

According to the filed complaint, during the class period, Becton Dickinson & Company made materially false and/or misleading statements and/or failed to disclose that: (1) certain of Becton's Alaris infusion pumps experienced software errors and alarm prioritization issues; (2) as a result, the Company was investing in remediation efforts to address these product issues, rather than a software upgrade to "make enhancements;" (3) the Company was reasonably likely to face regulatory delays in connection with the software remediation; (4) as a result of the foregoing, Becton was reasonably likely to recall certain of its Alaris infusion pumps; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

INO Lawsuit on behalf of: investors who purchased February 14, 2020 - March 9, 2020
Lead Plaintiff Deadline : May 12, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/inovio-pharmaceuticals-inc-loss-form?prid=5714&wire=1

According to a filed complaint, throughout the class period, defendants made misleading statements about the company's development of a purported vaccine for the novel coronavirus, artificially inflating the company's share price and resulting in significant investor losses.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP